A detailed history of Verition Fund Management LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 81,127 shares of BLUE stock, worth $744,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,127
Holding current value
$744,745
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.47 - $1.35 $38,129 - $109,521
81,127 New
81,127 $42,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $162,029 - $217,290
53,652 New
53,652 $163,000
Q4 2022

Feb 14, 2023

SELL
$5.77 - $8.49 $56,228 - $82,735
-9,745 Reduced 26.53%
26,992 $186,000
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $137,763 - $271,486
36,737 New
36,737 $233,000
Q3 2021

Nov 15, 2021

SELL
$11.24 - $21.0 $172,713 - $322,686
-15,366 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$18.04 - $22.09 $43,674 - $53,479
-2,421 Reduced 13.61%
15,366 $491,000
Q1 2021

May 18, 2021

BUY
$16.59 - $33.89 $295,086 - $602,801
17,787 New
17,787 $347,000
Q4 2020

Feb 16, 2021

SELL
$27.5 - $37.92 $110,082 - $151,793
-4,003 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$34.44 - $43.75 $71,325 - $90,606
-2,071 Reduced 34.1%
4,003 $216,000
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $164,726 - $279,221
6,074 New
6,074 $371,000
Q1 2020

May 15, 2020

SELL
$26.16 - $63.5 $118,138 - $286,766
-4,516 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$46.96 - $61.67 $212,071 - $278,501
4,516 New
4,516 $396,000
Q2 2019

Aug 14, 2019

SELL
$75.84 - $105.21 $568,648 - $788,864
-7,498 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$64.44 - $104.11 $483,171 - $780,616
7,498 New
7,498 $1.18 Million
Q2 2018

Aug 15, 2018

SELL
$99.64 - $127.59 $678,648 - $869,015
-6,811 Closed
0 $0
Q1 2018

May 16, 2018

BUY
$105.8 - $150.94 $720,603 - $1.03 Million
6,811 New
6,811 $1.16 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $708M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.